Possible significance of hemodynamic and immunomodulatory effects of early stress-dose steroids in cardiac arrest
© The Author(s). 2016
Published: 20 July 2016
The original article was published in Critical Care 2016 20:82
In an interesting randomized clinical trial (RCT), Donnino et al.  studied a mixed out-of-hospital cardiac arrest and in-hospital cardiac arrest (IHCA) population and found no hydrocortisone versus placebo hemodynamic or in-hospital outcome benefit. In the hydrocortisone group, the median time to study intervention was 9.9 h after return of spontaneous circulation (ROSC) . This time lag probably exceeds the therapeutic window for the prevention of detrimental episodes of early post-resuscitation hypotension  through a mean arterial pressure (MAP)-stabilizing effect of steroids [3, 4].
Survivors for ≥4 h with post-resuscitation shocka
VSE group (n = 103)
Control group (n = 88)
Time to discontinuation of vasopressors (days), median (IQR)b
Discontinuation of vasopressors during follow-up, n (%)
Estimated cumulative vasopressor dose (μg/kg) over the first 24 h post-ROSC, median (IQR)c,d,e
629 (321–1236) (n = 87)
Cumulative 24-h post-ROSC fluid balance (mL), mean ± SD
2168 ± 2398 (n = 78)
2034 ± 2198 (n = 60)
SAP >90 mmHg within 15–20 min post-ROSC, n (%)
76 (80.9) (n = 94)
40 (55.6) (n = 72)
At least 1 recorded/analyzed MAP value >80 mmHg over day 1, n (%)
82 (80.4) (n = 102)
35 (42.2) (n = 83)
ALS duration (min), median (IQR)
SAP >90 mmHg (n = 116)
SAP ≤90 mmHg (n = 50)
Survival to hospital discharge with CPC score of 1 or 2, n (%)
MAP >80 mmHg (n = 117)
MAP ≤80 mmHg (n = 68)
Survival to hospital discharge with CPC score of 1 or 2, n (%)
Recordings of “early post-ROSC SAP >90 mmHg” (i.e., “absence of early post-resuscitation hypotension” ) and “≥1 recorded/analyzed, day 1 MAP value of >80 mmHg ” were significantly more frequent in VSE patients than controls. Importantly, such SAP/MAP levels corresponded to more frequent survival to hospital discharge with favorable neurological outcome  (Table 1).
Early post-resuscitation hemodynamics of VSE patients could be partly attributable to the steroids-vasopressin combination during cardiopulmonary resuscitation (CPR) [3, 4]. However, a previously postulated major CPR-VSE effect, i.e., shorter advanced life support duration , possibly leading to attenuated post-resuscitation cardiovascular dysfunction was not clear in the current subgroup analysis (Table 1). Hence, according to the short (i.e., 24 min) half-life of vasopressin, we propose that the more frequent day 1 MAP >80 mmHg was largely due to a post-ROSC steroid-induced augmentation of vascular responsiveness to vasopressors [3, 4]. A mediation analysis of VSE outcome benefit through day 1 MAP is warranted. Analysis of day 1 MAP data from the study by Donnino et al. might causally link between-RCT differences in corticosteroid timing with differences in survival/neurological outcome results [1, 3, 4].
Post-resuscitation disease is a “sepsis-like” syndrome. In sepsis, acute kidney injury severity is associated with mortality and elevated interleukin (IL)-6. Furthermore, high post-ROSC IL-6 is associated with organ dysfunction and poor long-term outcomes . Notably, post-resuscitation hydrocortisone has been associated with reduced IL-6 levels [1, 3], and VSE patients versus controls had more renal failure-free days [3, 4].
Conclusively, available evidence prompts toward further evaluation of early, stress-dose steroids in cardiac arrest.
CPR, cardiopulmonary resuscitation; IHCA, in-hospital cardiac arrest; IL, interleukin; MAP, mean arterial pressure; RCT, randomized clinical trial; ROSC, return of spontaneous circulation; SAP, systolic arterial pressure; VSE, vasopressin-steroids-epinephrine
Availability of data and materials
For the purpose of the above-mentioned re-analysis protocol (Clinicaltrials.gov identifier, NCT02408939), we extracted individual peri-arrest and follow-up data from survivors for ≥4 h with post-resuscitation shock (n = 191) from an electronic masterfile containing de-identified data from references  and . Extracted, de-identified data was saved in a Microsoft Excel datafile. Data will not be shared because we plan to use it in a future mediation analysis mentioned in the fourth paragraph of the current main text.
SDM is responsible for the conception and drafting of the manuscript, conduct and accuracy of the data analyses, and interpretation of the results. NM, TX, and SGZ contributed to the interpretation of the results, and to critically important revisions of the original draft. All authors read and approved the final manuscript.
The authors declare that they have no competing interests.
Ethics approval and consent to participate
The pooled data analyses reported herein were performed as post hoc subanalyses of a re-analysis protocol of synthesized and de-identified data from references  and . The aforementioned re-analysis protocol has received the following Institutional Review Board (IRB) approvals: Evaggelismos General Hospital approval No. 14/9/1/2015; 401 Greek Army Hospital approval No. 3/2015/5/2/2015; and Larissa University Hospital approval No. 58905/2014/14/1/2015. Modifications of the aforementioned re-analysis protocol have been approved by the Evaggelismos IRB (respective approval Nos. 29/25/2/2016 and 30/25/2/2016), and these approvals were ratified by the IRBs of the other two participating centers (401 Greek Army Hospital, IRB Decision No.: 4-2016/6/4/2016; Larissa University Hospital, IRB Decision No.: 5/19-5-2016/Θ.18). All the aforementioned, de-identified data analyses were conducted under a waiver of informed consent, because they were not associated with any clinical intervention.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Donnino MW, Andersen LW, Berg KM, Collaborating authors from the Beth Israel Deaconess Medical Center’s Center for Resuscitation Science Research Group, et al. Corticosteroid therapy in refractory shock following cardiac arrest: a randomized, double-blind, placebo-controlled, trial. Crit Care. 2016;20:82.View ArticlePubMedPubMed CentralGoogle Scholar
- Trzeciak S, Jones AE, Kilgannon JH, et al. Significance of arterial hypotension after resuscitation from cardiac arrest. Crit Care Med. 2009;37:2895–903.View ArticlePubMedGoogle Scholar
- Mentzelopoulos SD, Zakynthinos SG, Tzoufi M, et al. Vasopressin, epinephrine, and corticosteroids for in-hospital cardiac arrest. Arch Intern Med. 2009;169:15–24.View ArticlePubMedGoogle Scholar
- Mentzelopoulos SD, Malachias S, Chamos C, et al. Vasopressin, steroids, and epinephrine and neurologically favourable survival after in-hospital cardiac arrest: a randomized clinical trial. JAMA. 2013;310:270–9.View ArticlePubMedGoogle Scholar
- Vaahersalo J, Skrifvars MB, Pulkki K, et al. Admission interleukin-6 is associated with post resuscitation organ dysfunction and predicts long-term neurological outcome after out-of-hospital ventricular fibrillation. Resuscitation. 2014;85:1573–9.View ArticlePubMedGoogle Scholar